News Conference News ACC 2026 Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering Michael O'Riordan April 01, 2026
News Conference News ACC 2026 SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients Michael O'Riordan March 30, 2026
News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
News Conference News ACC 2026 Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE Yael L. Maxwell March 28, 2026
News Conference News CRT 2026 DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients L.A. McKeown March 09, 2026
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Conference News ESC 2025 HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI Todd Neale September 03, 2025
News Conference News SCCT 2025 Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR Yael L. Maxwell July 28, 2025
News Conference News SCCT 2025 AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD Yael L. Maxwell July 22, 2025
News Conference News SCCT 2025 AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry Yael L. Maxwell July 21, 2025
News Conference News EuroPCR 2025 ‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI Michael O'Riordan May 29, 2025
News Conference News EuroPCR 2025 Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI Michael O'Riordan May 20, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024